MALAFRONTE MICHAEL W
Known title: DirectorCIK: 0001209162
MALAFRONTE MICHAEL W's purchase track record
How the stock did after each of MALAFRONTE MICHAEL W's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 6 since November 8, 2021
Stock higher 6 months later
83%
3 months: 83%
Median 6-month return
+29.0%
3 months: +23.9%
Beat the S&P 500
100%
median +19.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/11/2026 | CVSA | $897K | +28.8% | +24.5% | +12.7% |
| 3/3/2026 | CVSA | $2.86M | +19.1% | +30.1% | +11.9% |
| 11/4/2025 | CVSA | $92K | +7.8% | +28.0% | +7.2% |
| 3/7/2025 | CVSA | $87K | +41.2% | +48.0% | +12.3% |
| 2/10/2022 | CVSA | $1.25M | +35.2% | +65.7% | -6.6% |
| 11/8/2021 | CVSA | $709K | -13.8% | -4.1% | -15.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CVSA | ▼ Sell | Gift | 2,500 | $0 | 8/31/2026 | View on chart |
| CVSA | ▲ Buy | Open Market | 8,890 | $897K | 3/11/2026 | View on chart |
| CVSA | ▲ Buy | Open Market | 11,841 | $1.2M | 3/10/2026 | View on chart |
| CVSA | ▲ Buy | Open Market | 15,305 | $1.5M | 3/10/2026 | View on chart |
| CVSA | ▲ Buy | Open Market | 1,200 | $118K | 3/3/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 526 | $51K | 11/13/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 1,445 | $140K | 11/12/2025 | View on chart |
| CVSA | ▲ Buy | Open Market | 1,000 | $92K | 11/4/2025 | View on chart |
| CVSA | ▲ Buy | Open Market | 1,000 | $87K | 3/7/2025 | View on chart |
| CVSA | ▼ Sell | Gift | 5,000 | $0 | 12/13/2024 | View on chart |
| CVSA | ▲ Buy | Grant | 1,560 | $140K | 11/13/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 999 | $91K | 11/8/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,045 | $58K | 11/9/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 2,530 | $140K | 11/8/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,521 | $65K | 11/10/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 2,930 | $125K | 11/9/2022 | View on chart |
| CVSA | ▲ Buy | Open Market | 40,500 | $955K | 2/14/2022 | View on chart |
| CVSA | ▲ Buy | Open Market | 12,100 | $294K | 2/10/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 3,690 | $125K | 11/10/2021 | View on chart |
| CVSA | ▲ Buy | Open Market | 21,500 | $709K | 11/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update
Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.